Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | LIPE | Q05469 | 3/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514536 | 0.79 | SCN9A (0.47) | SCN9AMGLLLIPESCN10A | |
| SCHEMBL5506138 | 0.78 | P2RX7 (0.46) | — | |
| SCHEMBL14365302 | 0.77 | SCN9A (0.43) | SCN9AMGLLLIPESCN10A | |
| SCHEMBL5647120 | 0.69 | LIPE (0.71) | SCN9ALIPESCN10A | |
| SCHEMBL4130462 | 0.66 | DPP4 (0.38) | — | |
| SCHEMBL4500752 | 0.66 | HSD11B1 (0.39) | SCN9AMGLLLIPESCN10A | |
| SCHEMBL11411966 | 0.64 | THRB (0.58) | SCN9ALIPESCN10A | |
| SCHEMBL5504644 | 0.64 | HRH3 (0.41) | — | |
| SCHEMBL5500238 | 0.64 | DPP4 (0.41) | — | |
| SCHEMBL4516244 | 0.62 | SMN1; SMN2 (0.44) | SCN9ALIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | SCN9A 1272/4885MGLL 374/4885LIPE 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.